The role of BRCA1 in DNA double-strand repair: Past and present
Abstract
The breast cancer type 1 susceptibility protein (BRCA1) is involved in several important cellular pathways, including DNA damage repair, chromatin remodeling and checkpoint activation. The BRCA1 tumor suppression function has been attributed to its role in homologous recombination damage repair. In this review, historical facts concerning BRCA1, together with recent research advances regarding our understanding of the BRCA1 interacting proteins that are involved in, homologous recombination (HR) double strand break (DBS) repair and how these interacting proteins maintain chromosomal integrity, are discussed. In addition, this review poses the questions as to what extent HR repair cannot be properly fulfilled when breast cancer related mutations in the BRCA1 gene occur and how the recent and excessive studied poly-ADP ribose polymerase (PARP) inhibiting therapy approach links with the proposed tumor suppression function of the different BRCA1 domains.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The BRCA1-BARD1 complex acts in homologous recombination-mediated repair of DNA double-strand breaks.
“The tumor suppressor complex BRCA1-BARD1 functions in DNA double-strand break repair by homologous recombination.”
From BRCA1–BARD1 promotes RAD51-mediated homologous DNA pairing (2017) · cites this paper as [19]
The citation lists haven’t been fetched yet
References 107 · Cited by 108
- Authors
- Caestecker, K. W., & Van de Walle, G. R.
- Affiliations
- Ghent University (BE)
- Venue
- Experimental Cell Research
- Publisher
- Elsevier BV
- Published
- 2013-03
- Volume
- 319
- Issue
- 5
- Pages
- 575-587
- ISSN
- 0014-4827 (ISSN-L)
- OpenAlex
- W2109361580
- Cited by
- 108
- References
- 107
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 5 · 2023: 6 · 2022: 7 · 2021: 4 · 2020: 5 · 2019: 5 · 2018: 8 · 2017: 10 · 2016: 9 · 2015: 10 · 2014: 16 · 2013: 14
- FWCI
- 1.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Experimental Cell Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Universiteit Gent
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- BRCA1, DNA double-strand break repair, homologous recombination, chromosome integrity, tumor suppression, breast cancer susceptibility, chromatin remodeling, DNA damage checkpoint, PARP inhibitors
- MeSH terms
- Animals, Breast Neoplasms, DNA Repair, Female, Humans, Mutation, BRCA1 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
